导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.97% | 2809/4773 |
| 近一周 | -2.45% | 2204/5462 |
| 近一月 | -6.07% | 3438/5421 |
| 近一季 | 11.75% | 133/5209 |
| 近半年 | 0.77% | 1120/4920 |
| 近一年 | -15.42% | 3695/4366 |
| 近两年 | 18.37% | 2676/2954 |
| 近三年 | -10.79% | 2045/2253 |
| 成立以来 | -13.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.76% 3402/4961 |
-3.57% 3462/5312 |
- - |
- - |
| 2025 | 4.81% 3031/4813 |
0.69% 1787/3635 |
1.41% 2346/4076 |
19.76% 2101/4524 |
-14.29% 4339/4813 |
| 2024 | -11.90% 2362/3463 |
-11.23% 2420/2808 |
-9.51% 2370/3014 |
21.22% 606/3129 |
-9.52% 2932/3463 |
| 2023 | -13.47% 1544/2656 |
-1.55% 1875/2280 |
-9.14% 2040/2385 |
0.48% 366/2515 |
-3.73% 772/2655 |
| 2022 | -23.39% 1133/2207 |
-14.60% 978/1919 |
2.19% 1332/2016 |
-18.28% 1693/2113 |
7.43% 309/2208 |
| 2021 | -15.17% 1156/1822 |
-3.85% 829/1255 |
14.26% 262/1330 |
-16.22% 1398/1466 |
-7.84% 1576/1822 |
| 2020 | 53.09% 152/1250 |
3.33% 123/1028 |
26.64% 143/1067 |
5.00% 934/1164 |
11.41% 543/1184 |
| 2019 | - - |
- - |
- - |
- - |
6.92% 518/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达医药ETF联接C VS. 长安沪深300非周期A(740101) |